Fig. 5

The EP1/EP3-specific agonist 17ptE2 reverses the protective effect of the COX-2 inhibitor CAY10404. Dispersed OPCs treated with KA and the COX-2 inhibitor CAY (10 μM) resulted in a significant increase in surviving OPCs. When 17ptE2 (1 μM) was included with CAY, the protective effect was lost. Treatment with either CAY or 17ptE2 alone or in combination in the absence of KA was not toxic to OPCs (data not shown). In contrast to the other experiments where survival was assessed 48–144 h after addition of KA, in this experiment, survival was assessed 24 h after KA because of concerns of the chemical and metabolic stability of 17ptE2 with longer incubations. Significance was observed using ANOVA analyses. This result is representative of three different experiments